⌕
Summit Therapeutics · SMMT · Nasdaq
Tenet — · insufficient data
Compare
$11.82−16.47%At close
$11.82−2.33 (−16.47%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Summit Therapeutics (SMMT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 16, 2026 · 13:15 ETEARNINGS EXPECTED BY FEB 22
Summit Stock Falls on FDA Rejection for Lung Cancer Drug

SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.…

● Schaeffers ResearchNov 16, 2026 · 13:01 ET
2 Cancer-Drug Developers Seeing Unusual Options Volume

Two cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major clinical and regulatory dev…

● BarronsNov 16, 2026 · 08:42 ET
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.…

● Fool - Investing NewsNov 16, 2026 · 07:30 ETEARNINGS EXPECTED BY FEB 22
Breakfast News: Summit’s FDA Setback Isn’t the End

Summit falls on cancer drug approval setback, Nvidia headlines the week's earnings, and more……

● BenzingaNov 16, 2026 · 07:16 ET
Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles

Summit Therapeutics Inc. (NASDAQ:SMMT) is trading at a 52-week low on Monday after the FDA rejected the company's lead cancer drug application.…

● Investors Business DailyNov 15, 2026 · 14:34 ET
FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.…

● Business WireNov 15, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BL…

● Zacks Investment ResearchNov 10, 2026 · 10:56 ETEARNINGS EXPECTED BY FEB 22
Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 62.3% in Summit Therapeutics (SMMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend…

● Zacks Investment ResearchNov 5, 2026 · 08:40 ETEARNINGS EXPECTED BY FEB 22
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

Summit reports Q3 loss narrower than expected and posts nil sales. Ivonescimab advances through late-stage studies and new oncology collaborations.…

● Business WireNov 4, 2026 · 16:36 ETEARNINGS EXPECTED BY FEB 22
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operat…

● Business WireOct 25, 2026 · 11:52 ETEARNINGS EXPECTED BY FEB 22
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-c…

● PRNewsWireOct 23, 2026 · 21:26 ET
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (K…

● Business WireOct 23, 2026 · 16:37 ET
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered p…

● Zacks Investment ResearchOct 22, 2026 · 11:50 ET
Summit Expands Ivonescimab Development Into Biliary Tract Cancer

SMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.…

● Business WireOct 22, 2026 · 06:00 ET
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), tak…

● Zacks Investment ResearchOct 21, 2026 · 12:01 ET
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.…

● PRNewsWireOct 21, 2026 · 08:42 ETEARNINGS EXPECTED BY FEB 22
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.…

● Business WireOct 21, 2026 · 06:05 ET
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential …

● Business WireOct 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class inves…

● Zacks Investment ResearchOct 5, 2026 · 11:40 ET
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.…

● Business WireOct 5, 2026 · 07:00 ET
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support contin…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 22. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just SMMT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.